Pfizer: Its vaccine is 90.7% effective in children 5-11 years old

On October 22, pharmaceutical company Pfizer (USA) said that the COVID-19 vaccine produced by it in collaboration with pharmaceutical company BioNTech (Germany) was 90.7 percent effective against the SARS-CoV-2 virus. in children aged 5-11 years.

Pfizer-BioNTech's COVID-19 vaccine. Photo: AFP
Pfizer-BioNTech's COVID-19 vaccine. Photo: AFP

In a clinical trial report sent to the US Food and Drug Administration (FDA), Pfizer said 16 children who received a placebo injection had COVID-19, while only 3 children received the Pfizer vaccine/ BioNTech is sick. Of the 2,268 children participating in the trial, more than twice as many children received the Pfizer/BioNTech vaccine than the placebo group. Therefore, the effectiveness of this vaccine against COVID-19 in children is calculated to be more than 90%.

FDA advisers are scheduled to meet on October 26 to vote on whether to recommend that the agency approve Pfizer/BioNTech's vaccine for children ages 5-11. In the event that the FDA allows this vaccine to be given to children aged 5-11, the advisory group will continue to meet on November 2 and 3 to make recommendations on how to vaccinate.

Also on October 22, White House medical adviser Anthony Fauci said the US could deploy a booster dose with a different vaccine than the one previously injected, but still recommend only using one vaccine in the following cases. injection if there is enough vaccine.

In the US, the COVID-19 vaccine developed by Pfizer/BioNTech is currently available for use in people 12 years of age and older. About 190 million people in the US are fully immunized, including over 11 million people 12-17 years old who have been vaccinated with the Pfizer/BioNTech vaccine.

Google Tech News

Post a Comment

Previous Post Next Post